Developing Country Vaccine Markets

This presentation introduces a protocol and signaling approach for enabling the utilization of the first path in FTM protocol to enhance accuracy by avoiding blocked or attenuated LOS paths. It discusses the importance of optimizing beamforming training, adding capability bits, defining signaling methods for first path usage, and detailing the protocol for initiating and responding to FTM requests.

• IEEE
• FTM Protocol
• Beamforming Training
• Signaling
• Wireless Communication

bonn_ne Follow

Uploaded on Feb 26, 2025 | 0 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.

Presentation Transcript

1. Developing Country Vaccine Markets Presentation to 2015 DCVMN Meeting Amie Batson Chief Strategy Officer, PATH October 2015 PATH/Eric Becker

2. Agenda What is the developing country vaccine market? Globally financed developing country vaccine market Demand Supply Financing Opportunities and challenges for the future 2

3. Changing Demand Landscape - 2006 Source: UNICEF public data 3

4. Changing Demand Landscape - 2007 Source: UNICEF public data 4

5. Changing Demand Landscape - 2008 Source: UNICEF public data 5

6. Changing Demand Landscape - 2009 Source: UNICEF public data 6

7. Changing Demand Landscape - 2010 Source: UNICEF public data 7

8. Changing Demand Landscape - 2011 Source: UNICEF public data 8

9. Changing Demand Landscape - 2012 Source: UNICEF public data 9

10. Changing Demand Landscape - 2013 Source: UNICEF public data 10

11. Changing Demand Landscape - 2014 Source: UNICEF public data 11

12. New Product Combinations DTP Family 1998-2014 Source: UNICEF public data 12

13. New Product Combinations Measles Family 2014-2030 Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only 13

14. Increasing Value (UNICEF Contracts 2001-14) Source: UNICEF public data 14

15. New Markets (Gavi Graduation 2015-30) Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 15

16. New Markets (Gavi Graduation 2015-30) 57.7M Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 16

17. New Markets (Gavi Graduation 2015-30) 57.7M 150.1M Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 17

18. New Markets (Gavi Graduation 2015-30) 57.7M 150.1M 174.1M Source: PATH Global Vaccines Market Model. Provided for illustrative purposes only. 18

19. New Products in the Pipeline Source: WHO public data; PATH and partners analysis, July 2015 19

20. Examples of Manufacturers Leading the Way Chengdu Institute of Biological Products (CDIBP) Japanese encephalitis Serum Institute of India Ltd. Meningitis A 20

21. DCVM diversity Largest Parastatal Global Actors Emerging MNCs Product Portfolio/ Production Scale Niche Local New Entrants Gatekeepers State-owned Privately Held Market Driver 21

22. DCVM diversity Largest Parastatal Global Actors Emerging MNCs Product Portfolio/ Production Scale Niche Local Providers New Entrants State-owned Privately Held Market Driver 22

23. DCVM diversity Largest Parastatal Global Actors Emerging MNCs Product Portfolio/ Production Scale Niche Local Providers New Entrants State-owned Privately Held Market Driver Not exhaustive 23

24. Opportunities and Challenges for the Future Opportunities Challenges Shift to combination vaccine Creative partnership Access to high margin markets Lower Cost Market Knowledge GAVI Graduation Advantage for Regional Products? Regulatory Approval/PQ 24

25. Connect with Me www.path.org twitter.com/PATHtweets twitter.com/AmieBatson 25